Journals in Hematology

Best Practice & Research Clinical Haematology

ISSN: 1521-6926
5 Year impact factor: 2.3
Impact factor: 2.2

Best Practice & Research Clinical Haematology provides a comprehensive review of current clinical practice and thinking within the specialty of haematology.All chapters are commissioned and written by an international team of practicing clinicians with the Guest Editors for each issue drawn from a pool of renowned experts and opinion leaders.All chapters take the form of practical, evidence-based reviews that seek to address key clinical issues of diagnosis, treatment and patient management.Each issue follows a problem-orientated approach that focuses on the key questions to be addressed, clearly defining what is known and not known. Management will be described in practical terms so that it can be applied to the individual patient.Boxed and bulleted Learning Objectives and Practice Points are features within each chapter and will highlight the core and essential knowledge that will help the physician to provide the best care to their patients.

Subscriptions

Biochimica et Biophysica Acta: Proteins and Proteomics

ISSN: 1570-9639
5 Year impact factor: 2.8
Impact factor: 2.5

BBA Proteins and Proteomics covers protein structure conformation and dynamics; protein folding; protein-ligand interactions; enzyme mechanisms, models and kinetics; protein physical properties and spectroscopy; and proteomics and bioinformatics analyses of protein structure, protein function, or protein regulation.The journal no longer considers manuscripts dealing with binding of compounds such as drugs or drug analogues to circulatory proteins such as serum albumin. These studies are better accommodated in journals dealing with drug design and development.Manuscripts must advance our insights into the molecular and mechanistic properties of proteins. Computational studies must generally be validated or complemented by experimental studies. Studies only consisting of computational work will not be considered unless they provide new theoretical insight that allows us to better understand or reinterpret surprising or unexpected experimental data.Comparative proteomics studies are generally not considered for review unless they provide specific insights into the structural and/or functional properties of individual proteins. Proteomics studies must also address properties of individual proteins and should as far as possible be validated by direct investigations of relevant identified proteins.Concise and comprehensive reviews of recent developments are considered for publication. However, authors are strongly advised to consult one of the Executive Editors before starting a review.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Subscriptions

Blood

ISSN: 0006-4971
5 Year impact factor: 19.2
Impact factor: 21

Blood, the flagship journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Acceptance of manuscripts is based on the originality and importance of the observations or investigations, the quality of the work and validity of the evidence, the clarity of presentation, and the relevance to our readership and field. All articles are expected to be concise, well-organized and clearly written. Authors submit a manuscript with the understanding that the manuscript (or its essential substance) has not been published other than as an abstract in any language or format and is not currently submitted elsewhere for print or electronic publication.Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate. Authors are invited to submit a presubmission inquiry if they are uncertain whether their work falls within the general scope of the journal.Blood has formulated more precise scopes for immunobiology and immunotherapy, vascular biology, HIV/HTLV, and clinical trial submissions. The journal is very interested in submissions as reflected in the definitions linked below.Immunobiology and Immunotherapy scopeVascular Biology scopeHIV/HTLV scopeClinical Trials scopeBlood welcomes submission of manuscripts reporting on clinical trials whether phase 1, 2, 3 or 4. Reports should include a full description of the study design, patient population, methodology and conduct, and statistical plan.Immunobiology and Immunotherapy encompass a wide spectrum of research, but Blood can accommodate only papers that have clear and important implications for hematology. Preference is given to papers focusing on human immunobiology, immunotherapy, and immune pharmacology approaches in the human setting and those with significant implications for understanding of normal or malignant hematologic processes. Papers on tumor immunology, tumor vaccines and cancer immunotherapy development may be appropriate if the target cells or antigens are relevant to hematologic malignancies, but generally Blood cannot accommodate tumor immunology papers focusing solely on non-hematologic tumor types.Papers investigating autoimmunity and utilizing non-hematologic models are not within the scope of Blood.Vascular biology papers that focus primarily on atherosclerosis are outside the scope of Blood and instead should be considered for alternative journals.Papers felt to be outside the scope of Blood will be returned to the author without full peer review.

Subscriptions

Blood Cells, Molecules and Diseases

ISSN: 1079-9796
5 Year impact factor: 2.2
Impact factor: 2.1

BCMD is interested in contributions in basic, translational and clinical research focusing on the biology of blood cells and the pathophysiology of blood disorders, with a specific interest in non-malignant conditions.We will consider studies on hematological malignancies when secondary to inherited or acquired bone marrow failure or disorders of the immune system.Research Areas include:Erythropoiesis, Erythrocyte Biology, Hemoglobin and its disordersMyelopoiesis, myeloid cells and disorders of the myeloid lineage (incl. myeloproliferative disorders)Megakaryopoiesis and platelet disordersHemostasis & Thrombosis and disorders of coagulationTransfusion medicine and the study of therapeutic blood products (including novel biotechnologies related to transfusion products)Bone marrow failure (severe aplastic anemia, myelodysplasia, etc.)Immunodeficiency and dysregulation of the immune systemAuto-immune disorders relating to blood

Subscriptions

Blood Reviews

ISSN: 0268-960X
5 Year impact factor: 7.7
Impact factor: 6.9

This respected international journal, Blood Reviews, is a vital information resource, bringing together appraisals of clinical practice, and research from recognized experts. Specially commissioned peer reviewed articles from leading researchers and practitioners guarantee truly global coverage of all the sub-specialties of hematology.Blood Reviews publishes review articles covering the spectrum of clinical and laboratory haematological practice and research. Although most reviews are invited, the Editors welcome suggestions from potential authors. They should first write a brief outline of an intended review along with their publication record on topic and send this to Dr Drew Provan ([email protected]) or to Dr Hillard Lazarus ([email protected]). All articles are subject to peer review. Author queries can also be sent to the Blood Reviews editorial office [email protected]

Subscriptions

Cancer Genetics

ISSN: 0165-4608
5 Year impact factor: 1.7
Impact factor: 1.4

The aim of Cancer Genetics is to publish high quality scientific papers on the cellular, genetic and molecular aspects of cancer, including cancer predisposition and clinical diagnostic applications. Specific areas of interest include descriptions of new chromosomal, molecular or epigenetic alterations in benign and malignant diseases; novel laboratory approaches for identification and characterization of chromosomal rearrangements or genomic alterations in cancer cells; correlation of genetic changes with pathology and clinical presentation; and the molecular genetics of cancer predisposition. To reach a basic science and clinical multidisciplinary audience, we welcome original full-length articles, reviews, meeting summaries, brief reports, and letters to the editor.Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support CenterCancer Genetics is proud to be affiliated with the Cancer Genomics Consortium.

Subscriptions

Cancer Genetics

ISSN: 2210-7762
5 Year impact factor: 1.7
Impact factor: 1.4

Subscriptions

Cancer Treatment Reviews

ISSN: 0305-7372
5 Year impact factor: 10.9
Impact factor: 9.6

Cancer Treatment Reviews is an international journal that provides state of the art, authoritative review articles to the clinician and researcher to keep them abreast of modern concepts and the latest developments in cancer treatment research.Benefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support CenterJournal of Cancer Treatment Reviews' Inclusion and Diversity PledgeThis journal pledges to maintain diversity on the editorial team. This sits within Elsevier's broader ongoing inclusion & diversity efforts. Equity and inclusion in publishing is critically important for scientific excellence and innovation. We believe passionately in the power of an inclusive publishing environment, not only to do what is right, but to enrich, strengthen and advance us all.

Subscriptions

Critical Reviews in Oncology/Hematology

ISSN: 1040-8428
5 Year impact factor: 5.3
Impact factor: 5.5

Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world.The journal considers articles on the following themes:Basic Experimental OncologyCareer Development and Education in OncologyClinical ResearchHematologyImmunotherapyMolecular Pathology, Genomics and omics, and Liquid BiopsyPalliative SupportPediatric OncologyRadiotherapyRegulatory, Ethics, and Health PolicySolid TumorsStatistics, Meta-analysis, and Clinical Trial DesignSurgeryCritical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy (ISLB).All review articles, invited or submitted spontaneously, are subject to peer review before final acceptance. Further information regarding the submission of manuscripts and guidelines for the preparation of the manuscripts can be found in the Guide for Authors.

Subscriptions

Cytotherapy

ISSN: 1465-3249
5 Year impact factor: 4.3
Impact factor: 3.7

Cytotherapy, the official journal of the International Society for Cell & Gene Therapy (ISCT), publishes novel and innovative results from high quality scientific and clinical studies in the fields of cell, gene, and extracellular vesicle therapy.Cytotherapy considers manuscripts exploring the following topics:Development and/or characterization of novel gene therapies and cell and/or EV-based therapeutics.Design of novel therapeutic approaches employing cell/EV/gene products.Scientific mechanisms of action of cell/EV/gene therapies in relevant cell-based and pre-clinical models.Scientific mechanisms of action of toxicities attributable to cell/EV/gene therapiesIdentification of novel biomarkers that predict the potency of cell/EV/gene therapies and/or stratify patients based on response rates.Early and late phase clinical studies evaluating the safety and efficacy of cell/EV/gene therapies.Important advances in cell/EV/gene-based product manufacturing and validation.Global/regional regulatory practices that impact the authorized use and/or regulatory approval of cell/EV and gene therapies.Cytotherapy does not publish manuscripts on the following topics:Case studies unless they are of unusual significance to the field.Basic/translational studies exploring the role of lncRNAs, circRNAs, and miRNAs in disease pathophysiology.Fundamental scientific studies of normal or pathological processesStudies describing signaling pathways implicated in cancer.

Subscriptions

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Journals in Hematology

Best Practice & Research Clinical Haematology

Biochimica et Biophysica Acta: Proteins and Proteomics

Blood

Blood Cells, Molecules and Diseases

Blood Reviews

Cancer Genetics

Cancer Genetics

Cancer Treatment Reviews

Critical Reviews in Oncology/Hematology

Cytotherapy